Taxifolin attenuates doxorubicin-induced heart, liver, and kidney toxicity in mice via targeting TLR4
European Journal of Pharmacology · 2026-07 · 1030 · 179136
DOI: 10.1016/j.ejphar.2026.179136 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026-07. Verfasst von Mengting Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Changzhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, Changzhou, …. Hauptthemen laut MEDLINE: Quercetin, Doxorubicin, Toll-Like Receptor 4, Cardiotoxicity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Doxorubicin (DOX) is an effective anthracycline chemotherapeutic agent widely used for treating lymphoma, leukemia, and sarcoma, but its clinical application is severely restricted by dose-dependent cardiotoxicity, hepatotoxicity, and nephrotoxicity. This study aimed to investigate the mechanisms underlying DOX-induced multi-organ toxicity and identify targeted therapeutic natural compounds through an integrated approach combining network toxicology, virtual screening, molecular docking, molecular dynamics simulation, and in vivo validation. Potential targets were obtained by intersecting drug targets from SwissTargetPrediction, SuperPred, PharmMapper, DrugBank, TTD, ChEMBL, PubChem, and DGIdb databases with injury-related targets from GeneCards, OMIM, and TTD databases. Ten protein-protein interaction network analyses were performed to identify core targets, revealing 24 potential targets involved in DOX-induced toxicity. Gene Ontology enrichment analysis identified 1515 biological processes, 44 cellular components, and 90 molecular functions, while KEGG analysis highlighted 107 significant pathways including lipid and atherosclerosis-related signaling. TLR4 was prioritized as the top hub target, and reverse virtual screening of the natural product database identified taxifolin as a high-affinity candidate with favorable ADMET properties. Molecular docking and dynamics simulations confirmed stable taxifolin-TLR4 complex formation. In vivo experiments using a mouse model demonstrated that taxifolin significantly ameliorated serum biomarker elevations and histopathological damage in heart, liver, and kidney tissues while effectively suppressing TLR4 protein expression. These findings establish taxifolin as a promising TLR4-targeted natural therapeutic agent for mitigating DOX-induced multi-organ toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Changzhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, Changzhou, 213003, China.
- Department of Spleen and Stomach Diseases, Liyang Hospital of Chinese Medicine, Changzhou, 213300, China.
- Department of Gastroenterology, Changzhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, Changzhou, 213003, China. Electronic address: 2585884312@qq.com.
- The First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei, 230031, China. Electronic address: 17864190744@163.com.
Zitieren
APA
Jiang, M., Jiang, S., Ye, X., Qian, X., & Li, J. (2026). Taxifolin attenuates doxorubicin-induced heart, liver, and kidney toxicity in mice via targeting TLR4. European Journal of Pharmacology, 1030, 179136. https://doi.org/10.1016/j.ejphar.2026.179136
Vancouver
Jiang M, Jiang S, Ye X, Qian X, Li J. Taxifolin attenuates doxorubicin-induced heart, liver, and kidney toxicity in mice via targeting TLR4. European Journal of Pharmacology. 2026;1030:179136. doi:10.1016/j.ejphar.2026.179136
BibTeX
@article{Jiang2026,
author = {Jiang, Mengting and Jiang, Shunlei and Ye, Xiaofeng and Qian, Xin and Li, Jixu},
title = {Taxifolin attenuates doxorubicin-induced heart, liver, and kidney toxicity in mice via targeting TLR4},
journal = {European Journal of Pharmacology},
year = {2026},
volume = {1030},
pages = {179136},
doi = {10.1016/j.ejphar.2026.179136}
}
EUVIMED